{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:38:58Z","timestamp":1783125538158,"version":"3.54.6"},"reference-count":119,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T00:00:00Z","timestamp":1149811200000},"content-version":"vor","delay-in-days":1469,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Drug Reviews"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Imidapril hydrochloride (imidapril) is a long\u2010acting, non\u2010sulfhydryl angiotensin\u2010converting enzyme (ACE) inhibitor, which has been used clinically in the treatment of hypertension, chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy. It has the unique advantage over other ACE inhibitors in causing a lower incidence of dry cough. After oral administration, imidapril is rapidly converted in the liver to its active metabolite imidaprilat. The plasma levels of imidaprilat gradually increase in proportion to the dose, and decline slowly. The time to reach the maximum plasma concentration (T<jats:sub>max<\/jats:sub>) is 2.0 h for imidapril and 9.3 h for imidaprilat. The elimination half\u2010lives (t<jats:sub>1\/2<\/jats:sub>) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively. Imidapril and its metabolites are excreted chiefly in the urine. As an ACE inhibitor, imidaprilat is as potent as enalaprilat, an active metabolite of enalapril, and about twice as potent as captopril. In patients with hypertension, blood pressure was still decreased at 24 h after imidapril administration. The antihypertensive effect of imidapril was dose\u2010dependent. The maximal reduction of blood pressure and plasma ACE was achieved with imidapril, 10 mg once daily, and the additional effect was not prominent with higher doses. When administered to patients with AMI, imidapril improved left ventricular ejection fraction and reduced plasma brain natriuretic peptide (BNP) levels. In patients with mild\u2010to\u2010moderate CHF [New York Heart Association (NYHA) functional class II\u2010III], imidapril increased exercise time and physical working capacity and decreased plasma atrial natriuretic peptide (ANP) and BNP levels in a dose\u2010related manner. In patients with diabetic nephropathy, imidapril decreased urinary albumin excretion. Interestingly, imidapril improved asymptomatic dysphagia in patients with a history of stroke. In the same patients it increased serum substance P levels, while the angiotensin II receptor antagonist losartan was ineffective. These studies indicate that imidapril is a versatile ACE inhibitor. In addition to its effectiveness in the treatment of hypertension, CHF, and AMI, imidapril has beneficial effects in the treatment of diabetic nephropathy and asymptomatic dysphagia. Good tissue penetration and inhibition of tissue ACE by imidapril contributes to its effectiveness in preventing cardiovascular complications of hypertension. The major advantages of imidapril are its activity in the treatment of various cardiovascular diseases and lower incidence of cough compared with some of the older ACE inhibitors.<\/jats:p>","DOI":"10.1111\/j.1527-3466.2002.tb00185.x","type":"journal-article","created":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T10:46:06Z","timestamp":1281955566000},"page":"93-110","source":"Crossref","is-referenced-by-count":19,"title":["Protection of the Cardiovascular System by Imidapril, a Versatile Angiotensin\u2010Converting Enzyme Inhibitor"],"prefix":"10.1111","volume":"20","author":[{"given":"Kazuyoshi","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(98)00051-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90337-1"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501123320203"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199203000-00003"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb03898.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.6.1819"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60437-0"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209093071104"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1993.1066"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01459-3"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4800(81)90066-6"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250502"},{"issue":"3","key":"e_1_2_1_14_2","first-page":"S16","article-title":"Can captopril modify experimentally induced cardiac arrhythmias? (Abstract)","volume":"17","author":"Coker SJ","year":"1985","journal-title":"J Mol Cell Cardiol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/264451a0"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117243"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/5.2.95"},{"issue":"3","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0002-9343(88)90207-0","article-title":"Protective effect of captopril against ischemia\/reperfusion\u2010induced arrhythmias in vitro and in vivo","volume":"84","author":"Graeff PA","year":"1988","journal-title":"Am J Med"},{"key":"e_1_2_1_19_2","first-page":"181","article-title":"Concentration\u2010dependent protection by captopril against ischemia\u2010reperfusion injury in the isolated rat heart","volume":"280","author":"Graeff PA","year":"1986","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198700002-00009"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410080011002"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198509000-00003"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01906463"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.65.1.40"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199103000-00001"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.66.231"},{"key":"e_1_2_1_27_2","first-page":"176","article-title":"Bradykinin\u2010induced bronchoconstriction in humans. Mode of action","volume":"135","author":"Fuller RW","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_28_2","first-page":"1115","article-title":"GISSI\u20103: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6\u2010week mortality and ventricular function after acute myocardial infarction","volume":"343","author":"Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_29_2","first-page":"151","article-title":"1999 World Health Organization\u2010International Society of Hypertension Guidelines for the Management of Hypertension","volume":"17","author":"Guidelines Subcommittee.","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01036-4"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10327-1"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05012-0"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90958-K"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1096\/fasebj.2.1.2446942","article-title":"Substance P and astrocytes: Stimulation of the cyclooxygenase pathway of arachidonic acid metabolism","volume":"2","author":"Hartung HP","year":"1988","journal-title":"FASEB J"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.104.51"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00122a003"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1989.tb16881.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.3.672"},{"key":"e_1_2_1_40_2","first-page":"507","article-title":"Phase I study of TA\u20106366 (I) \u2010single oral administration","volume":"8","author":"Hirota Y","year":"1992","journal-title":"J Clin Ther Med"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(85)90587-3"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050421"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050236"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.2.613"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00930-9"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1981.241.1.F85"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-0952-7_12"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1159\/000047361"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-2-199301150-00009"},{"key":"e_1_2_1_50_2","first-page":"113","volume-title":"Contrib Nephrol.","author":"Katayama S.","year":"2001"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00320-4"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1980.48.3.511"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.5.2204"},{"key":"e_1_2_1_54_2","first-page":"446","article-title":"Effects of the new angiotensin\u2010I\u2010converting enzyme inhibitor imidapril on the responses of isolated vascular preparations to various agonists","volume":"42","author":"Kubo M","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.53.201"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1536\/jhj.40.645"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000137993"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2828(87)80619-3"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198706107-00012"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01869575"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2828(92)91103-C"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90301-L"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604113341502"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80448-Y"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.74.4.693"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(97)90028-2"},{"key":"e_1_2_1_68_2","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/0022-2828(89)91793-8","article-title":"Perindopril prevents fall in ventricullar fibrillation threshold and in cardiac output after coronary ligation in the pig. (Abstract)","volume":"21","author":"Muller CA","year":"1989","journal-title":"J Mol Cell Cardiol"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90263-9"},{"key":"e_1_2_1_70_2","first-page":"451","article-title":"Effects of the new angiotensin\u2010converting enzyme inhibitor imidapril on renal hemodynamics and function in anesthetized dogs","volume":"42","author":"Nishiyama S","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/27.2.334"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.6.1290"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.24.2.245"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(97)80021-X"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610023151402"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.81.4.1161"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.12.2643"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807143190204"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92377-9"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050105"},{"key":"e_1_2_1_82_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","article-title":"Long\u2010term renoprotective effect of angiotensin\u2010converting enzyme inhibition in non\u2010insulin\u2010dependent diabetes mellitus. A 7\u2010year follow\u2010up study","volume":"156","author":"Ravid M","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424849800300102"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641968709164198"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.22.197"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199509003-00005"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.23.317"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199109010-00002"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530430051039"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.76.3.489"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60114-6"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92758-A"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01857639"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90347-9"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90202-Z"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/137.2.331"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960200507"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00021-5"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05381-6"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-115-6-2332"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.100.39"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271002"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.18.64"},{"key":"e_1_2_1_104_2","first-page":"116","article-title":"The role of angiotensin converting enzyme on the pharmacokinetics of imidaprilat in rats","volume":"54","author":"Tagawa K","year":"1994","journal-title":"Yakuzaigaku"},{"key":"e_1_2_1_105_2","first-page":"157","article-title":"Pharmacokinetics of imidapril, a new angiotensin converting enzyme inhibitor, and imidaprilat, its active metabolite, in dogs","volume":"54","author":"Tagawa K","year":"1994","journal-title":"Yakuzaigaku"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199407000-00006"},{"key":"e_1_2_1_107_2","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.","year":"1993","journal-title":"Lancet"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_1_109_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"157","author":"The Joint National Committee.","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_1_111_2","first-page":"S138","article-title":"Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney","volume":"55","author":"Tojo A","year":"1996","journal-title":"Kidney INT"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90323-6"},{"key":"e_1_2_1_113_2","first-page":"722","article-title":"Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498","volume":"8","author":"Gilst WH","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00464-1"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.38.503"},{"key":"e_1_2_1_116_2","first-page":"130","article-title":"Does captopril attenuate reperfusion\u2010induced myocardial dysfunction by scavenging free radicals","volume":"77","author":"Westlin W","year":"1988","journal-title":"Circulation"},{"key":"e_1_2_1_117_2","first-page":"457","article-title":"Metabolic fate of the new angiotensin\u2010converting enzyme inhibitor imidapril in animals. 1st comunication: Absorption, pharmacokinetics and excretion in rats and dogs","volume":"42","author":"Yamada Y","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(95)01595-7"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.77.79"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00761-4"}],"container-title":["Cardiovascular Drug Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3466.2002.tb00185.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3466.2002.tb00185.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:21:00Z","timestamp":1700302860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3466.2002.tb00185.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1111\/j.1527-3466.2002.tb00185.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3466.2002.tb00185.x","archive":["Portico"],"relation":{},"ISSN":["0897-5957","1527-3466"],"issn-type":[{"value":"0897-5957","type":"print"},{"value":"1527-3466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}